6-氯-5-碘-3-硝基吡啶-2-胺 | 790692-90-9

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 6-氯-5-碘-3-硝基吡啶-2-胺
• 英文名称: 6-chloro-5-iodo-3-nitropyridin-2-amine
• CAS: 790692-90-9
• 化学式: C₅H₃ClIN₃O₂
• 分子量: 299.455
• InChiKey: FQFSWKVTOZFBOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H317,H319,H335

反应信息

• 作为反应物：
  描述：

  6-氯-5-碘-3-硝基吡啶-2-胺 在 铁粉 、 calcium chloride 作用下， 生成 6-Chloro-7-iodo-1,4-dihydro-pyrido[2,3-b]pyrazine-2,3-dione
  参考文献：
  名称：

  Synthesis and biological evaluation of pyrido[2,3-b]pyrazine and pyrido[2,3-b]pyrazine-n-oxide as selective glycine antagonists

  摘要：

  Pyrido[2,3-b]pyrazines and pyrido[2,3-b]pyrazines-N-oxides have been synthesized and evaluated for in vitro/in vivo antagonistic activity at the glycine site on the NMDA receptor. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00492-1
• 作为产物：
  描述：

  2-氨基-3-硝基-6-氯吡啶 在 silver(II) sulfate 、 碘 作用下， 以 乙醇 为溶剂， 以59%的产率得到6-氯-5-碘-3-硝基吡啶-2-胺
  参考文献：
  名称：

  PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF

  摘要：

  该发明涉及用于对抗哺乳动物体内肝吸虫寄生虫的口服、局部或注射组合物，包括至少一种苯并咪唑衍生物活性剂。该发明还提供了一种改进的方法，用于根除和控制哺乳动物体内肝吸虫寄生虫感染和寄生，包括向需要的哺乳动物体内施用该发明的组合物。

  公开号：

  US20130281392A1

文献信息

• Molecular recognition systems with pyrimidine analog pairing
  申请人：Benner Steven A

  公开号：US10059737B1

  公开（公告）日：2018-08-28

  This invention is for a new molecular recognition system, where DNA-like molecules comprising segments built from nucleotides that carry only a small which comprises process by which one molecule interacts with a specific second molecule, or by which a portion of a single molecule interacts specifically with another portion of the same molecule. Further, this invention relates to molecular recognition that follows simple rules. Further, this invention relates to molecular systems that are linear biopolymers that are analogs of DNA and RNA, in that they are built from a small set of building blocks that are linked together by phosphate groups, where the building blocks comprise a sugar (ribose, 2′-deoxyribose, or an analog) attached to a heterocycle. The molecular recognition that they display differs from that displayed by DNA and RNA, in that the rules governing molecular recognition break the rules of size complementarity followed in molecular recognition displayed between and within strands of DNA and RNA.

  该发明是一种新的分子识别系统，其中包括由核苷酸构建的片段组成的类似于DNA的分子，这些核苷酸只携带很小的一部分，其中包括一种分子与特定的第二种分子相互作用的过程，或者单个分子的一部分与同一分子的另一部分特异性地相互作用的过程。此外，该发明涉及遵循简单规则的分子识别。此外，该发明涉及线性生物聚合物的分子系统，这些聚合物类似于DNA和RNA，因为它们是由一小组建筑块组成的，这些建筑块由磷酸基连接在一起，其中建筑块包括连接在杂环上的糖（核糖，2'-去氧核糖或类似物）。它们展示的分子识别与DNA和RNA展示的不同，因为规则违反了在DNA和RNA链之间和内部展示的分子识别中遵循的大小互补规则。
• Inhibitors of akt activity
  申请人：Bilodeau T Mark

  公开号：US20060205765A1

  公开（公告）日：2006-09-14

  The present invention is directed to compounds which contain a five-membered heterocyclic ring fused to a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及化合物，其包含一个五元杂环环并到一个取代吡啶基团上，能够抑制Akt，一种丝氨酸/苏氨酸蛋白激酶的活性。本发明进一步涉及包含本发明化合物的化疗组合物，并且涉及使用本发明化合物治疗癌症的方法。
• Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20080275038A1

  公开（公告）日：2008-11-06

  The present disclosure relates to imidazopyridine derivatives of formula (I): The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及式(I)的咪唑吡啶衍生物。本公开还涉及一种用于治疗患有病理情况或易于通过A2B腺苷受体拮抗改善的疾病的受试者的方法。
• Imidazopyridine derivatives as A2B adenosine receptor antagonists
  申请人：Laboratorios Almirall, S.A.

  公开号：US07855202B2

  公开（公告）日：2010-12-21

  The present disclosure relates to imidazopyridine derivatives of formula (I): The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A2B adenosine receptor.

  本公开涉及式(I)的咪唑吡啶衍生物。本公开还涉及一种治疗由于A2B腺苷受体拮抗而可缓解的病理状态或疾病的方法。
• Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof
  申请人：Meng Charles Q

  公开号：US09000187B2

  公开（公告）日：2015-04-07

  The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one benzimidazole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

  本发明涉及口服、局部或注射用组合物，用于对抗哺乳动物体内的肝吸虫寄生虫，包括至少一种苯并咪唑衍生物活性剂。本发明还提供了一种改进的方法，用于根除和控制哺乳动物体内的肝吸虫寄生虫感染和寄生，包括向需要此类组合物的哺乳动物体内施用本发明的组合物。